Envisia Therapeutics
1
10M
1
0.12
- Areas of investment
Summary
In 2013 was created Envisia Therapeutics, which is appeared as Corporate Investor. The venture was found in North America in United States. The main department of described Corporate Investor is located in the Morrisville.
The important activity for fund was in 2014. The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 investment rounds annually.
The standard case for the fund is to invest in rounds with 3 partakers. The meaningful sponsors for the fund in investment in the same round are Correlation Ventures, Canaan Partners.
The fund was created by Benjamin Yerxa.
Moreover, a startup needs to be at the age of 1 and less years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline LQ3 Pharmaceuticals Among the most successful fund investment fields, there are Biotechnology, Pharmaceutical. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Rounds per year
- 0.12
- Investments by industry
- Biotechnology (1)
- Health Care (1)
- Pharmaceutical (1)
- Investments by region
-
- United States (1)
- Peak activity year
- 2014
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| LQ3 Pharmaceuticals | 10 Sep 2014 | Biotechnology, Health Care, Pharmaceutical | Early Stage Venture | 10M | United States, North Carolina |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.